Davide Seminati, Vincenzo L'Imperio, Gabriele Casati, Joranda Ceku, Daniela Pilla, Carla Rossana Scalia, Gianluca Gragnano, Francesco Pepe, Pasquale Pisapia, Luca Sala, Diego Luigi Cortinovis, Francesca Bono, Umberto Malapelle, Giancarlo Troncone, Silvia Novello, Fabio Pagni
BACKGROUND: The molecular diagnostic and therapeutic pathway of Non-Small Cell Lung Cancer (NSCLC) stands as a successful example of precision medicine. The scarcity of material and the increasing number of biomarkers to be tested have prompted the routine application of next-generation-sequencing (NGS) techniques. Despite its undeniable advantages, NGS involves high costs that may impede its broad adoption in laboratories. This study aims to assess the detailed costs linked to the integration of NGS diagnostics in NSCLC to comprehend their financial impact...
April 15, 2024: Heliyon